For One Small Device Company, A Big Company IP Strategy

Unlike many small medical device companies, Arthrocare insists it can implement an aggressive IP enforcement strategy because it has built a strong patent network around fundamentally new technology. Not only do the lawsuits stop patent infringers, they also give Arthrocare leverage it needs to initiate cross-licensing and licensing deals, gaining access to other important technologies. But inherent in this approach is a risk: uncertainty.

For the third time in just about as many years, ArthroCare Corp. , developers of the innovative Coblationtechnology used in orthopedic and a variety of other clinical applications, has sued a significantly larger rival, alleging patent infringement. ArthroCare's latest target: arthroscopy leader Smith & Nephew Dyonics Inc. , a division of Smith & Nephew PLC .

No one's keeping records, but ArthroCare's aggressive patent defense surely must place it among the most active small device companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Policy & Regulation

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.